Development of the Lung Transplant Frailty Scale (LT-FS)
Copyright © 2023 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved..
BACKGROUND: Existing measures of frailty developed in community dwelling older adults may misclassify frailty in lung transplant candidates. We aimed to develop a novel frailty scale for lung transplantation with improved performance characteristics.
METHODS: We measured the short physical performance battery (SPPB), fried frailty phenotype (FFP), Body Composition, and serum Biomarkers representative of putative frailty mechanisms. We applied a 4-step established approach (identify frailty domain variable bivariate associations with the outcome of waitlist delisting or death; build models sequentially incorporating variables from each frailty domain cluster; retain variables that improved model performance ability by c-statistic or AIC) to develop 3 candidate "Lung Transplant Frailty Scale (LT-FS)" measures: 1 incorporating readily available clinical data; 1 adding muscle mass, and 1 adding muscle mass and research-grade Biomarkers. We compared construct and predictive validity of LT-FS models to the SPPB and FFP by ANOVA, ANCOVA, and Cox proportional-hazard modeling.
RESULTS: In 342 lung transplant candidates, LT-FS models exhibited superior construct and predictive validity compared to the SPPB and FFP. The addition of muscle mass and Biomarkers improved model performance. Frailty by all measures was associated with waitlist disability, poorer HRQL, and waitlist delisting/death. LT-FS models exhibited stronger associations with waitlist delisting/death than SPPB or FFP (C-statistic range: 0.73-0.78 vs. 0.57 and 0.55 for SPPB and FFP, respectively). Compared to SPPB and FFP, LT-FS models were generally more strongly associated with delisting/death and improved delisting/death net reclassification, with greater improvements with increasing LT-FS model complexity (range: 0.11-0.34). For example, LT-FS-Body Composition hazard ratio for delisting/death: 6.0 (95%CI: 2.5, 14.2), SPPB HR: 2.5 (95%CI: 1.1, 5.8), FFP HR: 4.3 (95%CI: 1.8, 10.1). Pre-transplant LT-FS frailty, but not SPPB or FFP, was associated with mortality after transplant.
CONCLUSIONS: The LT-FS is a disease-specific physical frailty measure with face and construct validity that has superior predictive validity over established measures.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation - 42(2023), 7 vom: 13. Juli, Seite 892-904 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Singer, Jonathan P [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarker |
|---|
| Anmerkungen: |
Date Completed 19.06.2023 Date Revised 25.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.healun.2023.02.006 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354308939 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354308939 | ||
| 003 | DE-627 | ||
| 005 | 20240425232213.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.healun.2023.02.006 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM354308939 | ||
| 035 | |a (NLM)36925382 | ||
| 035 | |a (PII)S1053-2498(23)00049-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Singer, Jonathan P |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Development of the Lung Transplant Frailty Scale (LT-FS) |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.06.2023 | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Existing measures of frailty developed in community dwelling older adults may misclassify frailty in lung transplant candidates. We aimed to develop a novel frailty scale for lung transplantation with improved performance characteristics | ||
| 520 | |a METHODS: We measured the short physical performance battery (SPPB), fried frailty phenotype (FFP), Body Composition, and serum Biomarkers representative of putative frailty mechanisms. We applied a 4-step established approach (identify frailty domain variable bivariate associations with the outcome of waitlist delisting or death; build models sequentially incorporating variables from each frailty domain cluster; retain variables that improved model performance ability by c-statistic or AIC) to develop 3 candidate "Lung Transplant Frailty Scale (LT-FS)" measures: 1 incorporating readily available clinical data; 1 adding muscle mass, and 1 adding muscle mass and research-grade Biomarkers. We compared construct and predictive validity of LT-FS models to the SPPB and FFP by ANOVA, ANCOVA, and Cox proportional-hazard modeling | ||
| 520 | |a RESULTS: In 342 lung transplant candidates, LT-FS models exhibited superior construct and predictive validity compared to the SPPB and FFP. The addition of muscle mass and Biomarkers improved model performance. Frailty by all measures was associated with waitlist disability, poorer HRQL, and waitlist delisting/death. LT-FS models exhibited stronger associations with waitlist delisting/death than SPPB or FFP (C-statistic range: 0.73-0.78 vs. 0.57 and 0.55 for SPPB and FFP, respectively). Compared to SPPB and FFP, LT-FS models were generally more strongly associated with delisting/death and improved delisting/death net reclassification, with greater improvements with increasing LT-FS model complexity (range: 0.11-0.34). For example, LT-FS-Body Composition hazard ratio for delisting/death: 6.0 (95%CI: 2.5, 14.2), SPPB HR: 2.5 (95%CI: 1.1, 5.8), FFP HR: 4.3 (95%CI: 1.8, 10.1). Pre-transplant LT-FS frailty, but not SPPB or FFP, was associated with mortality after transplant | ||
| 520 | |a CONCLUSIONS: The LT-FS is a disease-specific physical frailty measure with face and construct validity that has superior predictive validity over established measures | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a biomarker | |
| 650 | 4 | |a body composition | |
| 650 | 4 | |a frailty | |
| 650 | 4 | |a lung transplantation | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Christie, Jason D |e verfasserin |4 aut | |
| 700 | 1 | |a Diamond, Joshua M |e verfasserin |4 aut | |
| 700 | 1 | |a Anderson, Michaela A |e verfasserin |4 aut | |
| 700 | 1 | |a Benvenuto, Luke A |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Arcasoy, Selim M |e verfasserin |4 aut | |
| 700 | 1 | |a Lederer, David J |e verfasserin |4 aut | |
| 700 | 1 | |a Calabrese, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Hays, Steven R |e verfasserin |4 aut | |
| 700 | 1 | |a Kukreja, Jasleen |e verfasserin |4 aut | |
| 700 | 1 | |a Venado, Aida |e verfasserin |4 aut | |
| 700 | 1 | |a Kolaitis, Nicholas A |e verfasserin |4 aut | |
| 700 | 1 | |a Leard, Lorriana E |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Rupal J |e verfasserin |4 aut | |
| 700 | 1 | |a Kleinhenz, Mary Ellen |e verfasserin |4 aut | |
| 700 | 1 | |a Golden, Jeffrey |e verfasserin |4 aut | |
| 700 | 1 | |a Betancourt, Legna |e verfasserin |4 aut | |
| 700 | 1 | |a Oyster, Michelle |e verfasserin |4 aut | |
| 700 | 1 | |a Zaleski, Derek |e verfasserin |4 aut | |
| 700 | 1 | |a Adler, Joe |e verfasserin |4 aut | |
| 700 | 1 | |a Kalman, Laurel |e verfasserin |4 aut | |
| 700 | 1 | |a Balar, Priya |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Shreena |e verfasserin |4 aut | |
| 700 | 1 | |a Medikonda, Nikhila |e verfasserin |4 aut | |
| 700 | 1 | |a Koons, Brittany |e verfasserin |4 aut | |
| 700 | 1 | |a Tevald, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Covinsky, Kenneth E |e verfasserin |4 aut | |
| 700 | 1 | |a Greenland, John R |e verfasserin |4 aut | |
| 700 | 1 | |a Katz, Patti K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation |d 1993 |g 42(2023), 7 vom: 13. Juli, Seite 892-904 |w (DE-627)NLM012612367 |x 1557-3117 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2023 |g number:7 |g day:13 |g month:07 |g pages:892-904 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.healun.2023.02.006 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2023 |e 7 |b 13 |c 07 |h 892-904 | ||